西罗莫司治疗结缔组织病相关难治性血小板减少的单臂开放标签临床试验
该单中心单臂II期研究纳入20例难治性结缔组织病相关血小板减少患者,口服西罗莫司调整剂量维持血药浓度6-15 ng/ml治疗6个月。结果显示60%患者达到主要终点,完全缓解率50%;14例SLE患者总缓解率71.4%、完全缓解率64.3%,而原发性干燥综合征患者均无应答,未观察到严重不良反应。
要点
- 西罗莫司治疗6个月时60%难治性CTD-TP患者达到主要终点,完全缓解率50%。
- SLE亚组总缓解率71.4%、完全缓解率64.3%,原发性干燥综合征患者均无应答。
- 应答者与非应答者基线临床特征及淋巴细胞亚群无显著差异,研究期间未发现严重副作用。
核心结论
- 西罗莫司是难治性结缔组织病相关血小板减少患者有效且安全的治疗选择。
研究设计与样本
- 单中心、单臂、II期临床试验,2017年9月至2018年9月纳入20例难治性CTD-TP患者,注册号NCT03688191。
- 口服西罗莫司剂量调整至治疗范围6-15 ng/ml,持续6个月。
- 主要终点为6个月时的部分缓解率和完全缓解率。
主要发现
- 14例SLE患者中总缓解率为71.4%,完全缓解率为64.3%。
- 原发性干燥综合征病例对西罗莫司均无应答。
- 应答者与非应答者基线临床特征或淋巴细胞亚群无显著差异。
- 研究期间未检测到严重副作用。
关键数值与推荐
- 西罗莫司治疗范围维持6-15 ng/ml,持续6个月。
- 主要终点为6个月时的部分缓解率和完全缓解率。
临床怎么用
- 对于糖皮质激素和/或免疫抑制剂无效的难治性CTD-TP患者,可考虑西罗莫司治疗并监测血药浓度6-15 ng/ml。
- SLE相关难治性血小板减少患者可能从西罗莫司获益,原发性干燥综合征患者可能不应答。
局限性
- 单中心、单臂设计,样本量20例,无对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Connective tissue disease-related thrombocytopenia (CTD-TP) is a problematic disorder in clinical practice. Because the first-line therapy of glucocorticoid and/or immunosuppressants is not effective for refractory cases, alternative treatment approaches are urgently needed. The present study investigated the efficacy and safety of sirolimus in refractory CTD-TP patients. METHODS: This single-centre, single-arm, phase II study enrolled 20 refractory CTD-TP patients between September 2017 and September 2018 (registered on ClinicalTrials.gov: NCT03688191). Oral sirolimus administration was dose-adjusted to maintain a therapeutic range of 6-15 ng/ml for 6 months. The primary endpoints were partial and complete remission rates at 6 months. RESULTS: Twelve (60%) patients achieved the primary end point with a 50% complete remission rate after 6 months. Among the 14 SLE patients, the overall response rate was 71.4%, with a complete remission rate of 64.3%. None of the primary Sjögren's syndrome cases responded to sirolimus. There was no significant difference in baseline clinical characteristics or lymphocyte subpopulations between responders and non-responders. No severe side effect was detected during the study. CONCLUSION: Sirolimus is an effective and safe treatment option for refractory CTD-TP patients. TRIAL REGISTRATION: https://clinicaltrials.gov, NCT03688191.
引用
- Wu C, Wang Q, Xu D, et al. Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial. Rheumatology (Oxford). 2021. PMID: 33200217. doi:10.1093/rheumatology/keaa645
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。